Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Université Paris-Sud · Inserm · +23 more institutions
Abstract
Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an…
Citation impact
- FWCI
- 175.26
- Percentile
- 100%
- References
- 35
Authors
48- BRBertrand Routy
Université Paris-Sud, Inserm, Université Paris-Saclay, Institut Gustave Roussy, La Ligue Contre le Cancer
- ELEmmanuelle Le Chatelier
Université Paris-Saclay
- LDLisa Derosa
Université Paris-Sud, Inserm, Université Paris-Saclay, Institut Gustave Roussy, La Ligue Contre le Cancer
- CPConnie P.M. Duong
Inserm, Institut Gustave Roussy, La Ligue Contre le Cancer
- MTMaryam Tidjani Alou
Université Paris-Sud, Inserm, Université Paris-Saclay, Institut Gustave Roussy, La Ligue Contre le Cancer
Topics & keywords
- Akkermansia muciniphila
- Blockade
- Microbiome
- Medicine
- CXCR3
- Immunotherapy
- Cancer
- Fecal bacteriotherapy
- Good health and well-being